Biocon, Amylin Pharma ink pact to develop and market novel peptide hybrid for diabetes

Biocon Limited and Amylin Pharmaceuticals Inc have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes.

The details can be read here.